Ticlopidine in China: comparative study on the effect of two dose levels on bleeding time and platelet function in healthy volunteers.
The compared inhibitory effects of two dose levels of ticlopidine (250 and 500 mg/day) on bleeding time and platelet function in Chinese volunteers have been studied in a placebo-controlled study. Ticlopidine exerted several significant effects: namely prolongation of bleeding time, inhibition of ADP-induced platelet aggregation, reduction of the thromboxane B2 synthesis induced by collagen as well as by ADP. The daily dose of 250 mg did not show significantly different effects as compared to the western, usually recommended daily dose of 500 mg. At the daily dose of 500 mg, adverse reactions occurred more frequently than at the daily dose of 250 mg, but no serious side effects necessitating discontinuation of treatment, or abnormalities in hematological and liver function parameters were observed at these two dose levels. In Chinese people, ticlopidine therapy should be administered at a daily dose of 250 mg.
Ruan
C
C
Thrombosis and Hemostasis Research Unit, Suzhou Medical College, China.
Destelle
G
G
Wang
Z
Z
Wan
H
H
He
Y
Y
Cheng
D
D
Li
P
P
Duffas
M
M
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000284:Administration, Oral; D000328:Adult; D001760:Bleeding Time; D002681:China; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010979:Platelet Function Tests; D013929:Thromboxane B2 / Q000096:biosynthesis; D013988:Ticlopidine / Q000008:administration & dosage / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D000244:Adenosine Diphosphate; D003094:Collagen; D013988:Ticlopidine